CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have been assigned a consensus recommendation of “Hold” from ...

After hours: March 12 at 7:59:48 PM EDT Loading Chart for CRSP ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note issued to investors on Wednesday,Benzinga reports.The brokerage ...

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the shares. While Casgevy is making progress based on 2024 ...

Stifel analyst Benjamin Burnett lowered the firm’s price target on Crispr Therapeutics (CRSP) to $49 from $53 and keeps a Hold rating on the shares. The firm’s neutral thesis on the stock is ...

O n Friday, Citi analysts adjusted their outlook on CRISPR Therapeutics (NASDAQ:CRSP) stock, reducing the price target to $82 from $89 while maintaining a Buy rating. The stock, which has shown ...

A new review in Engineering reveals that CRISPR technologies are revolutionizing regenerative medicine. Scientists from ...